BridgeMD
New treatment option for Thymoma and Thymic Carcinoma
Official title Hypofractionated Radiotherapy for Thymic Epithelial Tumors
ClinicalTrials.gov ID: NCT06692062
What this study is testing
- What it's testing
- The goal of this clinical trial is to learn if hypofractionated radiotherapy works to shorten the treatment time without increasing the side effects in patients of thymic epithelial tumors. The main questions it aims to answer are: Does Hypofractionated radiotherapy provide better results?
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Patients must provide written informed consent.
- 18 years old ≤ age \<75 years old.
- Thymoma confirmed by pathology: type A, type AB, type B1, type B2, type B3. Thymic carcinoma. Patients with previous thymectomy were required to have...
- Masaoka⁃Koga ⁃ stage Ⅰ-Ⅲ
- ECOG performance status 0-2.
You likely can't join if
- patients with prior thoracic radiotherapy;
- diseases not suitable for radiotherapy, such as recent myocardial infarction, active congestive heart failure;
- Uncontrolled infectious disease or other serious medical or mental illness that may interfere with care
- Patients with other malignant tumors that are not under stable control;
- Known history of mental illness, substance abuse, alcohol or drug abuse.
- Other conditions deemed unsuitable for enrollment by the attending physician.
See the full eligibility criteria
- Patients must provide written informed consent.
- 18 years old ≤ age \<75 years old.
- Thymoma confirmed by pathology: type A, type AB, type B1, type B2, type B3. Thymic carcinoma. Patients with previous thymectomy were required to have complete surgical related data.
- Masaoka⁃Koga ⁃ stage Ⅰ-Ⅲ
- ECOG performance status 0-2.
- Expected survival time \> 1 year.
- Participants of childbearing age must agree to use effective contraception during the trial; In women of childbearing age, a serum or urine pregnancy test must be negative.
- Patients who are not lactating.
- Sufficient bone marrow reserve and good function of important organs.
- patients with prior thoracic radiotherapy;
- diseases not suitable for radiotherapy, such as recent myocardial infarction, active congestive heart failure;
- Uncontrolled infectious disease or other serious medical or mental illness that may interfere with care
- Patients with other malignant tumors that are not under stable control;
- Known history of mental illness, substance abuse, alcohol or drug abuse.
- Other conditions deemed unsuitable for enrollment by the attending physician.
The study team makes the final eligibility decision.
Where it's taking place
- Changsha, Hunan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Changsha, Hunan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.